Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764740 | 0.91 | TP53 (0.53) | KIF11TP53MAPTABCG2SMN1; SMN2 | |
| SCHEMBL8404381 | 0.85 | KIF11 (0.47) | KIF11TP53MAPTABCG2SMN1; SMN2 | |
| SCHEMBL8403147 | 0.84 | KIF11 (0.49) | KIF11TP53MAPTABCG2 | |
| SCHEMBL8404438 | 0.81 | ABCG2 (0.53) | KIF11TP53MAPTABCG2SMN1; SMN2 | |
| SCHEMBL764051 | 0.80 | TP53 (0.51) | KIF11TP53MAPTABCG2SMN1; SMN2 | |
| SCHEMBL8402709 | 0.77 | KIF11 (0.58) | KIF11TP53MAPTABCG2ABCB1 | |
| SCHEMBL12978975 | 0.75 | KIF11 (0.49) | KIF11TP53MAPTABCG2SMN1; SMN2 | |
| SCHEMBL3344851 | 0.75 | TP53 (0.59) | KIF11TP53MAPTABCG2SMN1; SMN2 | |
| SCHEMBL9962250 | 0.75 | TP53 (0.59) | KIF11TP53MAPTABCG2SMN1; SMN2 | |
| SCHEMBL3344853 | 0.75 | TP53 (0.59) | KIF11TP53MAPTABCG2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | KIF11 2890/4885TP53 61/4885MAPT 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.